Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, January 24, 2024.
Cognito Therapeutics has enrolled its first patients in a sensory neurostim biomarker study. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the trial will look like and how executives see this transforming treatment option.
The UK NHS Trust treated the first patients with Allurion’s weight loss balloon. Learn more about the technology and the results from the first treatments.
A former Boston Scientific executive joined the board of directors of pulsed field ablation company Mirai Medical. Whooley talks about their career history and what Mirai Medical is doing.
Earnings season is upon us, and Johnson & Johnson MedTech has reported a 13% sales uptick in Q4. Hear more updates from the Abiomed acquisition and how the company’s electrophysiology portfolio is doing.
A new report claims that Samsung is joining Apple in the non-invasive glucose monitor battle. The Fast Five hosts talk about the implications this could have on the glucose monitoring market and if there’s a projected timeline.
Follow the Fast Five hosts on LinkedIn
Subscribe to the Fast Five daily news podcast on your preferred listening platform. If you’re on a desktop computer, scan the QR code below with your smartphone to easily access the podcast on your mobile device.
Listen to previous episodes here.